Last reviewed · How we verify
Madopar monotherapy
Madopar combines levodopa and benserazide to increase dopamine levels in the brain by delivering levodopa across the blood-brain barrier while benserazide blocks its peripheral conversion.
Madopar is a combination of levodopa and benserazide that increases dopamine levels in the brain by providing the dopamine precursor while inhibiting its peripheral metabolism. Used for Parkinson's disease.
At a glance
| Generic name | Madopar monotherapy |
|---|---|
| Sponsor | Peking University Third Hospital |
| Drug class | Dopamine precursor / Decarboxylase inhibitor combination |
| Target | Dopamine pathway; aromatic L-amino acid decarboxylase (peripheral inhibition by benserazide) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine in the central nervous system. Benserazide is a peripheral decarboxylase inhibitor that prevents levodopa from being converted to dopamine outside the brain, thereby increasing the amount of levodopa available for central conversion and reducing peripheral side effects. This combination allows lower doses of levodopa to be effective while minimizing gastrointestinal and cardiovascular adverse effects.
Approved indications
- Parkinson's disease
Common side effects
- Nausea
- Dizziness
- Dyskinesia
- Orthostatic hypotension
- Insomnia
- Hallucinations
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Madopar monotherapy CI brief — competitive landscape report
- Madopar monotherapy updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI